The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.

Adrián Sánchez-Fdez,Sofía Matilla-Almazán,Juan Carlos Montero,Sofía Del Carmen,Mar Abad,Sara García-Alonso,Somshuvra Bhattacharya,Kristin Calar,Pilar de la Puente,Alberto Ocaña,Atanasio Pandiella,Azucena Esparís-Ogando

Clinical and translational medicine（2023）

引用 0|浏览11

暂无评分

摘要

The present study uncovers the participation of WNK1-MEK5-ERK5 axis in ovarian cancer pathophysiology, opening the possibility of acting on this pathway with therapeutic purposes. Another important finding of the present study was the activation of that signalling axis by trametinib, bypassing the anti-tumoural efficacy of this drug. That fact should be considered in the context of the use of trametinib in ovarian cancer.

查看译文

关键词

ERK5,MEK5,WNK1,ovarian cancer,patient biopsies,trametinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要